Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Publications

Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Perspective and future direction of intraventricular mechanical dyssynchrony assessment.

PMID: 30684259
Journal: JOURNAL OF NUCLEAR CARDIOLOGY
Year: 2021
Reference: J Nucl Cardiol. 2021 Feb;28(1):65-71. doi: 10.1007/s12350-019-01604-3. Epub 2019 Jan 25.
Impact factor: 5.952
Publication type: Editorail in international publication
Authors: Romero-Farina, Guillermo, Aguade-Bruix, Santiago et al.
DOI: 10.1007/s12350-019-01604-3

Perspective and future direction of intraventricular mechanical dyssynchrony assessment.

PMID: 30684259
Journal: JOURNAL OF NUCLEAR CARDIOLOGY
Year: 2021
Reference: J Nucl Cardiol. 2021 Feb;28(1):65-71. doi: 10.1007/s12350-019-01604-3. Epub 2019 Jan 25.
Impact factor:
Publication type: Editorail in international publication
Authors: Aguade-Bruix, Santiago; Romero-Farina, Guillermo et al.
DOI: 10.1007/s12350-019-01604-3

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

PMID: NOPMID0090
Journal: Cancer Drug Resistance
Year: 2021
Reference: Cancer Drug Resistance. 2021;4(1):44-68.
Impact factor: 0
Publication type: Review in international publication
Authors: Ulldemolins, Anna, Seras-Franzoso, Joaquin, Andrade, Fernanda, Rafael, Diana, Abasolo, Ibane, Gener, Petra, Schwartz, Simo et al.
DOI: 10.20517/cdr.2020.59

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

PMID: NOPMID0090
Journal: Cancer Drug Resistance
Year: 2021
Reference: Cancer Drug Resistance. 2021;4(1):44-68.
Impact factor:
Publication type: Review in international publication
Authors: Abasolo, Ibane; Andrade, Fernanda; Gener, Petra; Rafael, Diana; Schwartz, Simo; Seras-Franzoso, Joaquin; Ulldemolins, Anna et al.
DOI: 10.20517/cdr.2020.59

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics.

PMID: 35582007
Journal: Cancer Drug Resistance
Year: 2021
Reference: Cancer Drug Resist. 2021 Mar 19;4(1):44-68. doi: 10.20517/cdr.2020.59. eCollection 2021.
Impact factor:
Publication type: Review in international publication
Authors: Abasolo, Ibane; Andrade, Fernanda; Gener, Petra; Rafael, Diana; Schwartz, Simo Jr; Seras-Franzoso, Joaquin; Ulldemolins, Anna et al.
DOI: 10.20517/cdr.2020.59

Pharmaceutical interventions in the emergency department: cost-effectiveness and cost-benefit analysis.

PMID: 35049519
Journal: European Journal of Hospital Pharmacy
Year: 2021
Reference: Eur J Hosp Pharm. 2021 May;28(3):133-138. doi: 10.1136/ejhpharm-2019-002067. Epub 2020 Feb 25.
Impact factor: 1.652
Publication type: Paper in international publication
Authors: Miarons, Marta, Marin, Sergio, Amenos, Imma, Campins, Lluis, Rovira, Montse, Daza, Manuel et al.
DOI: 10.1136/ejhpharm-2019-002067

Pharmaceutical interventions in the emergency department: cost-effectiveness and cost-benefit analysis.

PMID: 35049519
Journal: European Journal of Hospital Pharmacy
Year: 2021
Reference: Eur J Hosp Pharm. 2021 May;28(3):133-138. doi: 10.1136/ejhpharm-2019-002067. Epub 2020 Feb 25.
Impact factor:
Publication type: Paper in international publication
Authors: Amenos, Imma; Campins, Lluis; Daza, Manuel; Marin, Sergio; Miarons, Marta; Rovira, Montse et al.
DOI: 10.1136/ejhpharm-2019-002067

Pharmacogenetics of trough serum anti-TNF levels in pediatric inflammatory bowel disease.

PMID: 32478906
Journal: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Year: 2021
Reference: Br J Clin Pharmacol. 2021 Feb;87(2):447-457. doi: 10.1111/bcp.14400. Epub 2020 Jul 1.
Impact factor:
Publication type: Paper in international publication
Authors: Abarca-Zabalia, Judith; Alvarez-Vayo, Concepcion; Aznal, Elena; Balboa-Vega, Maria Jesus; Blanca-Garcia, Jose A; Bossacoma, Ferran; Clemente, Susana; de Caldas, Rafael Gonzalez; Eizaguirre, Francisco J; Gallego-Fernandez, Carmen et al.
DOI: 10.1111/bcp.14400

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease.

PMID: 34603940
Journal: Current treatment options in rheumatology
Year: 2021
Reference: Curr Treatm Opt Rheumatol. 2021;7(4):319-333. doi: 10.1007/s40674-021-00186-x. Epub 2021 Sep 28.
Impact factor: 0
Publication type: Review in international publication
Authors: Sanchez-Pernaute, O, Pinal-Fernandez, I, Ruiz-Rodriguez, J C, Gil-Vila, A, Trallero-Araguas, E, Romero-Bueno, F, Selva-O'Callaghan, A et al.
DOI: 10.1007/s40674-021-00186-x

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease.

PMID: 34603940
Journal: Current treatment options in rheumatology
Year: 2021
Reference: Curr Treatm Opt Rheumatol. 2021;7(4):319-333. doi: 10.1007/s40674-021-00186-x. Epub 2021 Sep 28.
Impact factor:
Publication type: Review in international publication
Authors: Gil-Vila, A; Pinal-Fernandez, I; Romero-Bueno, F; Ruiz-Rodriguez, J C; Sanchez-Pernaute, O; Selva-O'Callaghan, A; Trallero-Araguas, E et al.
DOI: 10.1007/s40674-021-00186-x

Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.

PMID: 34664531
Journal: Expert Review of Clinical Pharmacology
Year: 2021
Reference: Expert Rev Clin Pharmacol. 2021 Dec;14(12):1551-1560. doi: 10.1080/17512433.2021.1986004. Epub 2021 Nov 8.
Impact factor:
Publication type: Paper in international publication
Authors: Badiu, Corin; Biagetti, Betina; Durand-Gasselin, Lucie; Neggers, Sebastian; Petit, Anne; Petrossians, Patrick; Regnault, Benjamin; Rich, David; Shafigullina, Zulfiya; Shustov, Sergey et al.
DOI: 10.1080/17512433.2021.1986004

Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.

PMID: 32915419
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2021
Reference: Invest New Drugs. 2021 Feb;39(1):193-201. doi: 10.1007/s10637-020-00944-z. Epub 2020 Sep 11.
Impact factor:
Publication type: Paper in international publication
Authors: Azaro, Analia; Baldini, Capucine; Benhadji, Karim A; Lithio, Andrew; Massard, Christophe; Oakley, Gerard; Rodon, Jordi; Soria, Jean-Charles; Yuen, Eunice et al.
DOI: 10.1007/s10637-020-00944-z

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours.

PMID: 33941878
Journal: BRITISH JOURNAL OF CANCER
Year: 2021
Reference: Br J Cancer. 2021 Jul;125(1):28-37. doi: 10.1038/s41416-021-01389-8. Epub 2021 May 3.
Impact factor:
Publication type: Paper in international publication
Authors: Argiles, Guillem; Connolly, Roisin M; de Jonge, Maja; Dobson, Jason R; Garralda, Elena; Giannakis, Marios; Janku, Filip; Ji, Yan; McLaughlin, Margaret E; Moody, Susan E et al.
DOI: 10.1038/s41416-021-01389-8

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.

PMID: 33148674
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. Epub 2020 Nov 4.
Impact factor: 12.531
Publication type: Paper in international publication
Authors: Won, Helen H, Bond, John, Jones, Surai, Savage, Heidi M, Scaltriti, Maurizio, Wilson, Timothy R, Wei, Michael C, Hyman, David M, Dunn, Lara, Sachdev, Jasgit C et al.
DOI: 10.1158/1078-0432.CCR-20-2657

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.

PMID: 33148674
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. Epub 2020 Nov 4.
Impact factor:
Publication type: Paper in international publication
Authors: Aljumaily, Raid; Bedard, Philippe L; Bond, John; Chang, Matthew T; Dunn, Lara; Gambardella, Valentina; Hyman, David M; Jhaveri, Komal; Jones, Surai; Juric, Dejan et al.
DOI: 10.1158/1078-0432.CCR-20-2657

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

PMID: 34385069
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2021
Reference: Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9.
Impact factor: 9.162
Publication type: Paper in international publication
Authors: Matos, Ignacio, Villacampa, Guillermo, Garralda, Elena, Dienstmann, Rodrigo, Tabernero, Josep, Felip, Enriqueta, Hierro, Cinta, Martin-Liberal, Juan, Berche, Roger, Pedrola, Anna et al.
DOI: 10.1016/j.ejca.2021.05.040

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

PMID: 34385069
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2021
Reference: Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso, Guzman; Azaro, Analia; Berche, Roger; Brana, Irene; Carles, Joan; Dienstmann, Rodrigo; Elez, Elena; Felip, Enriqueta; Galvao, Vladimir; Gardeazabal, Itziar et al.
DOI: 10.1016/j.ejca.2021.05.040

Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

PMID: 33046517
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.
Impact factor: 12.531
Publication type: Paper in international publication
Authors: Di Martino, Jorge, Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Isambert, Nicolas, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, Martin-Romano, Patricia et al.
DOI: 10.1158/1078-0432.CCR-20-2380

Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

PMID: 33046517
Journal: CLINICAL CANCER RESEARCH
Year: 2021
Reference: Clin Cancer Res. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12.
Impact factor:
Publication type: Paper in international publication
Authors: Arias, Marina; Aronchik, Ida; Baudin, Eric; Capdevila, Jaume; Curigliano, Giuseppe; de Alvaro, Juan; de Bono, Johann S; Di Martino, Jorge; Filvaroff, Ellen H; Hollebecque, Antoine et al.
DOI: 10.1158/1078-0432.CCR-20-2380

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and GM-CSF in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

PMID: 33942954
Journal: ONCOLOGIST
Year: 2021
Reference: Oncologist. 2021 Sep;26(9):e1508-e1513. doi: 10.1002/onco.13810. Epub 2021 May 22.
Impact factor:
Publication type: Paper in international publication
Authors: Babiker, Hani M; Brana, Irene; Calvo, Emiliano; Crittenden, Marka; Feng, Minjie; Formenti, Silvia; Fury, Matthew; Garrido, Pilar; Giralt, Jordi; Hervas-Moron, Asuncion et al.
DOI: 10.1002/onco.13810

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.

PMID: 33452559
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2021
Reference: Cancer Chemother Pharmacol. 2021 Apr;87(4):543-553. doi: 10.1007/s00280-020-04214-w. Epub 2021 Jan 15.
Impact factor: 3.333
Publication type: Paper in international publication
Authors: Lopez-Vivanco, Guillermo, Gonzalez Cebrian, Irene, Casado Gonzalez, Esther, Mondejar Solis, Rebeca, Feliu, Jaime, Jorge Fernandez, Monica, Macarulla, Teresa, Massuti, Bartomeu, Albero, Ana, Gonzalez Gonzalez, Jose Federico et al.
DOI: 10.1007/s00280-020-04214-w

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.

PMID: 33452559
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2021
Reference: Cancer Chemother Pharmacol. 2021 Apr;87(4):543-553. doi: 10.1007/s00280-020-04214-w. Epub 2021 Jan 15.
Impact factor:
Publication type: Paper in international publication
Authors: Albero, Ana; Casado Gonzalez, Esther; Delgado-Mingorance, Juan Ignacio; Feliu, Jaime; Fernandez Montes, Ana; Garcia Piernavieja, Carmen; Gonzalez Cebrian, Irene; Gonzalez Gonzalez, Jose Federico; Jorge Fernandez, Monica; Lopez Munoz, Ana Maria et al.
DOI: 10.1007/s00280-020-04214-w

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

PMID: 34452745
Journal: GYNECOLOGIC ONCOLOGY
Year: 2021
Reference: Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25.
Impact factor: 5.482
Publication type: Paper in international publication
Authors: Oaknin, Ana, Monk, Bradley J, Selle, Frederic, Rojas, Carlos, Gladieff, Laurence, Berton, Dominique, Leary, Alexandra, Moore, Kathleen N, Estevez-Diz, Maria D P, Hardy-Bessard, Anne-Claire et al.
DOI: 10.1016/j.ygyno.2021.08.018

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.

PMID: 34452745
Journal: GYNECOLOGIC ONCOLOGY
Year: 2021
Reference: Gynecol Oncol. 2021 Nov;163(2):274-280. doi: 10.1016/j.ygyno.2021.08.018. Epub 2021 Aug 25.
Impact factor:
Publication type: Paper in international publication
Authors: Alexandre, Jerome; Ancukiewicz, Marek; Berton, Dominique; de Azevedo, Carla Rameri A S; Estevez-Diz, Maria D P; Feliu, Waldo Ortuzar; Gladieff, Laurence; Hardy-Bessard, Anne-Claire; Leary, Alexandra; Monk, Bradley J et al.
DOI: 10.1016/j.ygyno.2021.08.018